Specifically, the expressions of RRM1, ERCC1, and TUBB3 are inversely correlated with tumor responses to anti-metabolites such as gemcitabine, platinum-based agents, and spindle poisons, respectively, which may help explain why these drugs have shown little efficacy in vivo [31] or in clinical studies [32, 33]. Here, RRM1 is linked to neoplasm.